BASEL (dpa-AFX) - Silence Therapeutics plc.(SLN.L) said that licence holder
Quark Pharmaceuticals Inc. has confirmed favourable results in its Phase 2 trial
for the use of QPI-1002 short interfering RNA or siRNA for the prevention of
Amgen (NASDAQ: AMGN) today announced that a Phase 3 study evaluating AMG 416 (formerly known as velcalcetide) for the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease (CKD), receiving hemodialysis, met its...
Atara Biotherapeutics Inc., a company in which Mexican billionaire Carlos Slim owns shares, filed for an initial public offering to expand kidney disease research - an illness that runs in the Slim family.
Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the
development of therapeutics targeting significant unmet life-threatening
diseases, today announced that it has completed enrollment of
By Leif Peterson:
The annual prevalence of end-stage renal disease (ESRD) in the US is approximately 500,000, and is growing every year because of the obesity epidemic. ESRD occurs at the later stages of chronic kidney disease, which is primarily...
Oops! Unable to complete your request. Please refresh your browser.